News

OMERACT to Consider 'Absence of Disease' as Outcome


 

NEW YORK — Building on the work in developing a clinical definition of remission in rheumatoid arthritis, a group of clinicians and researchers is interested in creating a complementary patient term called “absence of disease.”

Rheumatologists from around the world will begin discussing how to develop this patient-centered definition in Malaysian Borneo in May at the next meeting of OMERACT (Outcome Measures in Rheumatology), an international network aimed at improving outcomes assessment in rheumatology.

It's important to ask patients for their view of what “absence of disease” means, because they see “remission” so differently from the way physicians do, Dr. Maarten Boers, a member of the OMERACT executive committee, said at a rheumatology course sponsored by New York University. The current remission term is a classic physician-centric definition that is largely based on inflammation, he said.

“If you talk to patients, they talk about totally different things than we talk about in terms of disease,” Dr. Boers, a professor at VU University Medical Center in Amsterdam, said in an interview.

Although patients were involved in developing the remission definition by OMERACT, that dimension wasn's fully studied. This time around, the organization plans to spend about 2 years performing qualitative work. They won's have to start from scratch, though, Dr. Boers said, because there has already been qualitative work done on a related issue: the impact of disease, which could be interpreted as the opposite of the “absence of disease” concept.

Disclosures: Dr. Boers said he had no relevant financial disclosures to make.

Recommended Reading

Gout Risk Factors Similar for Women and Men
MDedge Rheumatology
Treat Pain Plus Major Symptom in Fibromyalgia
MDedge Rheumatology
Exercise, Support Groups Benefit Many Fibromyalgia Patients
MDedge Rheumatology
Novel Drug Improves Methotrexate-Resistant RA
MDedge Rheumatology
RA Progression Hinges on Genetics, Lifestyle, and Gender
MDedge Rheumatology
Framingham Risk Score Falls Short in RA Patients
MDedge Rheumatology
Vaccination Rates Lag in Rheumatic Disease Patients
MDedge Rheumatology
Misclassifying Spondyloarthritis: MRI Held Risky
MDedge Rheumatology
Chronic Musculoskeletal Pain Raises Risk of Falling in Elderly
MDedge Rheumatology
FDA Flags Liver Damage Risks With Diclofenac
MDedge Rheumatology